BioPharCO

Biopharma de Colombia que necesitaba 36 meses para la aprobación de INVIMA mientras ELaboratorio desplazaba a la farmacéutica privada en la adquisición pública

Declive de años antes del cierre final · Error fatal: Colombia biopharma: INVIMA (national pharma regulator) clinical trial approval took 36+ months for novel biologics. Plan Vallejo (manufacturing export tax exemption) required 70% export commitment. INVIMA biosimilar pathway was not approved until 2021. ELaboratorio (national public pharma) crowded out private biopharma in public procurement. No viable commercial biopharma market without 36-month regulatory runway.